Bone Biologics Corp. (BBLG)
0.5615
0.00 (0.00%)
USD |
NASDAQ |
Sep 09, 16:00
0.5615
0.00 (0.00%)
After-Hours: 18:27
Bone Biologics Enterprise Value : -3.018M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | -3.018M |
| September 04, 2026 | -3.003M |
| September 03, 2026 | -3.022M |
| September 02, 2026 | -3.035M |
| September 01, 2026 | -3.012M |
| August 31, 2026 | -2.987M |
| August 28, 2026 | -2.918M |
| August 27, 2026 | -2.918M |
| August 26, 2026 | -2.917M |
| August 25, 2026 | -2.937M |
| August 24, 2026 | -2.932M |
| August 21, 2026 | -2.898M |
| August 20, 2026 | -2.936M |
| August 19, 2026 | -2.873M |
| August 18, 2026 | -2.867M |
| August 17, 2026 | -2.837M |
| August 14, 2026 | -2.846M |
| August 13, 2026 | -2.811M |
| August 12, 2026 | -2.841M |
| August 11, 2026 | -2.386M |
| August 10, 2026 | -2.439M |
| August 07, 2026 | -2.344M |
| August 06, 2026 | -2.367M |
| August 05, 2026 | -2.258M |
| August 04, 2026 | -2.321M |
| Date | Value |
|---|---|
| August 03, 2026 | -2.402M |
| July 31, 2026 | -2.501M |
| July 30, 2026 | -2.475M |
| July 29, 2026 | -2.394M |
| July 28, 2026 | -2.292M |
| July 27, 2026 | -2.176M |
| July 24, 2026 | -2.095M |
| July 23, 2026 | -2.077M |
| July 22, 2026 | -2.040M |
| July 21, 2026 | -2.022M |
| July 20, 2026 | -2.004M |
| July 17, 2026 | -1.914M |
| July 16, 2026 | -1.859M |
| July 15, 2026 | -1.787M |
| July 14, 2026 | -1.751M |
| July 13, 2026 | -1.678M |
| July 10, 2026 | -1.515M |
| July 09, 2026 | -1.533M |
| July 08, 2026 | -1.606M |
| July 07, 2026 | -1.370M |
| July 06, 2026 | -1.425M |
| July 02, 2026 | -1.461M |
| July 01, 2026 | -1.497M |
| June 30, 2026 | -1.552M |
| June 29, 2026 | -2.052M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.79B |
| Oncolytics Biotech, Inc. | 96.67M |
| Sangamo Therapeutics, Inc. | 58.40M |
| Sarepta Therapeutics, Inc. | 2.469B |
| Anixa Biosciences, Inc. | 83.62M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.7737M |
| Total Expenses (Quarterly) | 0.7737M |
| EPS Diluted (Quarterly) | -0.4306 |
| Earnings Yield | -286.7% |
| Normalized Earnings Yield | -286.87 |